Ergoteles LLC Takes $286,000 Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Posted by on Mar 5th, 2023

Ergoteles LLC bought a new stake in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,374 shares of the company’s stock, valued at approximately $286,000.

Other hedge funds have also recently modified their holdings of the company. Great West Life Assurance Co. Can bought a new position in shares of Reata Pharmaceuticals during the third quarter valued at approximately $38,000. US Bancorp DE grew its stake in shares of Reata Pharmaceuticals by 930.5% during the first quarter. US Bancorp DE now owns 1,824 shares of the company’s stock valued at $60,000 after buying an additional 1,647 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Reata Pharmaceuticals by 176.8% in the third quarter. Tower Research Capital LLC TRC now owns 2,881 shares of the company’s stock worth $72,000 after purchasing an additional 1,840 shares in the last quarter. UBS Group AG grew its stake in Reata Pharmaceuticals by 42.2% in the second quarter. UBS Group AG now owns 2,558 shares of the company’s stock worth $78,000 after purchasing an additional 759 shares in the last quarter. Finally, Macquarie Group Ltd. grew its stake in Reata Pharmaceuticals by 51.1% in the second quarter. Macquarie Group Ltd. now owns 2,768 shares of the company’s stock worth $84,000 after purchasing an additional 936 shares in the last quarter. Institutional investors own 76.13% of the company’s stock.

Reata Pharmaceuticals Stock Up 4.7 %

Shares of NASDAQ RETA opened at $90.87 on Friday. The stock’s fifty day simple moving average is $44.03 and its two-hundred day simple moving average is $35.38. Reata Pharmaceuticals, Inc. has a 12-month low of $18.47 and a 12-month high of $95.00.

Analyst Ratings Changes

Several brokerages recently issued reports on RETA. Stifel Nicolaus increased their price objective on Reata Pharmaceuticals from $75.00 to $105.00 in a research note on Wednesday. Barclays increased their price objective on Reata Pharmaceuticals from $50.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday. The Goldman Sachs Group increased their price objective on Reata Pharmaceuticals from $115.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, February 24th. Cantor Fitzgerald increased their price objective on Reata Pharmaceuticals from $61.00 to $121.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Citigroup increased their price objective on Reata Pharmaceuticals from $53.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $95.00.

Reata Pharmaceuticals Company Profile

(Get Rating)

Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Featured Stories

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.